Shiyao Li

Nov 1, 2024 | pubs.rsc.org | Jun Jiang |Shiyao Li |Honghao Chen |Yue Qiu

Achieving the Selectivity of Oxygen Reduction Reactions by Regulating Electron Spin States and Active Centers on Fe-Mn-N6-C Dual-atom Catalysts The relationship between the catalytic activity and selectivity of transition metal-based atom-dispersed catalysts and their spin states is a fundamental yet intricate aspect of their functionality. Despite considerable research efforts, elucidating the precise correlation between spin dynamics and catalytic performance remains elusive.

Sep 19, 2024 | dx.doi.org | Stephen Kent |Shiyao Li |Thakshila Amarasena |Arnold Reynaldi

Lipid nanoparticle mRNA vaccines have revolutionized vaccinology and saved countless lives during the COVID-19 pandemic. (1) Lipid nanoparticle mRNA vaccines typically contain 5 materials─mRNA, an ionizable lipid, a poly(ethylene glycol) (PEG) –lipid, a helper lipid, and cholesterol.

Sep 9, 2024 | mdpi.com | Chun-Ming Yang |Tian Chen |Shiyao Li |Chang-Hsien Hsu

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 27, 2024 | medrxiv.org | Stephen J. Kent |Shiyao Li |Thakshila Amarasena |Arnold Reynaldi

The authors have declared no competing interest. This study was supported by the Australian Research Council (ARC) Discovery Project (DP210103114 to FC, SJK and YJ), the National Health and Medical Research Council (NHMRC) program grant (GNT1149990 to SJK and MPD), the Victorian Critical Vaccinees Collection COVID-19 Research Seed Funding Grant (YJ), an ARC Discovery Early Career Researcher Award (DE230101542 to YJ), and NHMRC Investigator grants (SJK, WSL, GNT2016732 to FC, JAJ, AKW, and MPD).

Aug 30, 2023 | dx.doi.org | Yutian Ma |Shiyao Li |Xin Lin |Yupeng Chen

Ribonucleic acid (RNA)-based therapies have become an attractive topic in disease intervention, especially with some that have been approved by the FDA such as the mRNA COVID-19 vaccine (Comirnaty, Pfizer-BioNTech, and Spikevax, Moderna) and Patisiran (siRNA-based drug for liver delivery). However, extensive applications are still facing challenges in delivering highly negatively charged RNA to the targeted site.